This causes a progressive reduction in the volume of the prostate lobe (a volume reduction of at least 40% compared to the basal volume at one-year follow-up) and the subsequent disappearance of the symptoms.
The planning of the treatment, the insertion of the needles and the monitoring are all carried out under ultrasound guidance.
To facilitate insertion, the system has a dedicated transrectal ultrasound probe multi-applicator Guiding System with the relative Planning Software that displays the guidelines and the estimated ablation area on the ultrasound system screen.
With just one SoracteLite session it is possible to obtain a significant and persistent reduction of the prostate gland volume and an improvement of localised symptoms, without changing the prostate’s physiology.